{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T01:46:38Z","timestamp":1794620798509,"version":"4.9.1"},"reference-count":152,"publisher":"Elsevier","isbn-type":[{"value":"9780128168448","type":"print"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1016\/bs.apcsb.2019.08.009","type":"book-chapter","created":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T08:37:44Z","timestamp":1578645464000},"page":"157-198","source":"Crossref","is-referenced-by-count":19,"title":["Inflammatory bowel disease and targeted oral anti-TNF\n                    <mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" altimg=\"si1.svg\">\n                      <mml:mrow>\n                        <mml:mtext>\u03b1\u00a0<\/mml:mtext>\n                      <\/mml:mrow>\n                    <\/mml:math>\n                    therapy"],"prefix":"10.1016","member":"78","reference":[{"issue":"4","key":"10.1016\/bs.apcsb.2019.08.009_bib1","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20130044","article-title":"Characterization of the complex formed between a potent neutralizing ovine-derived polyclonal anti-TNF\u03b1 Fab fragment and human TNF\u03b1","volume":"33","author":"Abbott","year":"2013","journal-title":"Bioscience Reports"},{"issue":"21","key":"10.1016\/bs.apcsb.2019.08.009_bib2","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMra0804647","article-title":"Inflammatory bowel disease","volume":"361","author":"Abraham","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1016\/bs.apcsb.2019.08.009_bib4","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/ibd.20413","article-title":"Hepatocyte nuclear factor 4alpha in the intestinal epithelial cells protects against inflammatory bowel disease","volume":"14","author":"Ahn","year":"2008","journal-title":"Inflammatory Bowel Diseases"},{"issue":"4","key":"10.1016\/bs.apcsb.2019.08.009_bib5","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s10151-011-0759-4","article-title":"Local injection of infliximab in severe fistulating perianal Crohn's disease: An open uncontrolled study","volume":"15","author":"Alessandroni","year":"2011","journal-title":"Techniques in Coloproctology"},{"key":"10.1016\/bs.apcsb.2019.08.009_bib6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jim.2017.03.023","article-title":"An oral administration of a recombinant anti-TNF fusion protein is biologically active in the gut promoting regulatory T cells: Results of a phase I clinical trial using a novel oral anti-TNF alpha-based therapy","volume":"446","author":"Almon","year":"2017","journal-title":"Journal of Immunological Methods"},{"issue":"8","key":"10.1016\/bs.apcsb.2019.08.009_bib7","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/ibd.20137","article-title":"Another paradox in Crohn's disease: New onset of psoriasis in a patient receiving tumor necrosis factor-alpha antagonist","volume":"13","author":"Angelucci","year":"2007","journal-title":"Inflammatory Bowel Diseases"},{"issue":"4","key":"10.1016\/bs.apcsb.2019.08.009_bib8","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2217\/imt.15.4","article-title":"Investigating the potential side effects of anti-TNF therapy for rheumatoid arthritis: Cause for concern?","volume":"7","author":"Atzeni","year":"2015","journal-title":"Immunotherapy"},{"issue":"9853","key":"10.1016\/bs.apcsb.2019.08.009_bib9","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0140-6736(12)60026-9","article-title":"Crohn's disease","volume":"380","author":"Baumgart","year":"2012","journal-title":"The Lancet"},{"key":"10.1016\/bs.apcsb.2019.08.009_bib10","series-title":"Nobel lecture: Serum therapy in therapeutics and medical science","author":"von Behring","year":"1901"},{"issue":"1","key":"10.1016\/bs.apcsb.2019.08.009_bib11","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.autrev.2013.06.002","article-title":"Optimizing anti-TNF treatments in inflammatory bowel disease","volume":"13","author":"Ben-Horin","year":"2014","journal-title":"Autoimmunity Reviews"},{"issue":"3","key":"10.1016\/bs.apcsb.2019.08.009_bib12","doi-asserted-by":"crossref","first-page":"e0174275","DOI":"10.1371\/journal.pone.0174275","article-title":"Elevated fecal peptidase D at onset of colitis in Galphai2-\/- mice, a mouse model of IBD","volume":"12","author":"Bergemalm","year":"2017","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/bs.apcsb.2019.08.009_bib13","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1097\/MIB.0b013e3182a11958","article-title":"AVX-470: A novel oral anti-TNF antibody with therapeutic potential in inflammatory bowel disease","volume":"19","author":"Bhol","year":"2013","journal-title":"Inflammatory Bowel Diseases"},{"issue":"3","key":"10.1016\/bs.apcsb.2019.08.009_bib14","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40506-017-0130-z","article-title":"Discovering drugs for the treatment of ebola virus","volume":"9","author":"Bixler","year":"2017","journal-title":"Current Treatment Options in Infectious Diseases"},{"issue":"6","key":"10.1016\/bs.apcsb.2019.08.009_bib15","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/0016-5085(94)90398-0","article-title":"Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease","volume":"106","author":"Breese","year":"1994","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/bs.apcsb.2019.08.009_bib17","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.crohns.2013.01.010","article-title":"The burden of inflammatory bowel disease in Europe","volume":"7","author":"Burisch","year":"2013","journal-title":"Journal of Crohn\u2019s & Colitis"},{"issue":"3","key":"10.1016\/bs.apcsb.2019.08.009_bib18","first-page":"262","article-title":"Colonic proteinases: Increased activity in patients with ulcerative colitis","volume":"58","author":"Bustos","year":"1998","journal-title":"Medicina"},{"key":"10.1016\/bs.apcsb.2019.08.009_bib21","first-page":"CD000545","article-title":"Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease","volume":"10","author":"Chande","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1016\/bs.apcsb.2019.08.009_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/s12276-018-0126-x","article-title":"Mechanisms regulating intestinal barrier integrity and its pathological implications","volume":"50","author":"Chelakkot","year":"2018","journal-title":"Experimental & Molecular Medicine"},{"issue":"5","key":"10.1016\/bs.apcsb.2019.08.009_bib23","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1177\/2040622315586970","article-title":"Vedolizumab: An \u03b14\u03b27 integrin antagonist for ulcerative colitis and Crohn's disease","volume":"6","author":"Cherry","year":"2015","journal-title":"Therapeutic Advances in Chronic Disease"},{"key":"10.1016\/bs.apcsb.2019.08.009_bib24","article-title":"Allergic and immunologic perspectives of inflammatory bowel disease","author":"Clarke","year":"2018","journal-title":"Clinical Reviews in Allergy and Immunology"},{"issue":"3","key":"10.1016\/bs.apcsb.2019.08.009_bib25","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/labinvest.3700050","article-title":"A porous defense: The leaky epithelial barrier in intestinal disease","volume":"84","author":"Clayburgh","year":"2004","journal-title":"Laboratory Investigation; a Journal of Technical Methods and Pathology"},{"key":"10.1016\/bs.apcsb.2019.08.009_bib26","article-title":"Intestinal epithelium in inflammatory bowel disease","volume":"1","author":"Coskun","year":"2014","journal-title":"Frontiers of Medicine"},{"issue":"6","key":"10.1016\/bs.apcsb.2019.08.009_bib27","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.bbadis.2012.01.012","article-title":"TNF-\u03b1-induced down-regulation of CDX2 suppresses MEP1A expression in colitis","volume":"1822","author":"Coskun","year":"2012","journal-title":"Biochimica et Biophysica Acta"},{"issue":"1","key":"10.1016\/bs.apcsb.2019.08.009_bib29","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1038\/s41598-018-23277-7","article-title":"Preclinical development of a novel, orally-administered anti-tumour necrosis factor domain antibody for the treatment of inflammatory bowel disease","volume":"8","author":"Crowe","year":"2018","journal-title":"Scientific Reports"},{"issue":"2637","key":"10.1016\/bs.apcsb.2019.08.009_bib30","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1136\/bmj.2.2637.108","article-title":"Administration of serum by the mouth","volume":"2","author":"Cumberlege","year":"1911","journal-title":"British Medical Journal"},{"issue":"18","key":"10.1016\/bs.apcsb.2019.08.009_bib31","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMra1102942","article-title":"Ulcerative colitis","volume":"365","author":"Danese","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"7405","key":"10.1016\/bs.apcsb.2019.08.009_bib33","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nature11225","article-title":"Dietary fat-induced taurocholic acid production promotes pathobiont and colitis in IL-10\u2212\/\u2212 mice","volume":"487","author":"Devkota","year":"2012","journal-title":"Nature"},{"key":"10.1016\/bs.apcsb.2019.08.009_bib35","doi-asserted-by":"crossref","first-page":"437","DOI":"10.4049\/jimmunol.83.4.437","article-title":"The lack of absorption of ingested bovine antibody in humans","volume":"83","author":"Dixon","year":"1959","journal-title":"The Journal of Immunology"},{"issue":"1","key":"10.1016\/bs.apcsb.2019.08.009_bib36","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0016-5085(95)90277-5","article-title":"Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)","volume":"109","author":"van Dullemen","year":"1995","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/bs.apcsb.2019.08.009_bib37","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1136\/gut.37.1.58","article-title":"Faecal mucinase activity assessed in inflammatory bowel disease using 14C threonine labelled mucin substrate","volume":"37","author":"Dwarakanath","year":"1995","journal-title":"Gut"},{"issue":"2","key":"10.1016\/bs.apcsb.2019.08.009_bib38","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/0090-1229(84)90078-3","article-title":"T-cell abnormalities in inflammatory bowel disease are mediated by interleukin 2","volume":"33","author":"Ebert","year":"1984","journal-title":"Clinical Immunology and Immunopathology"},{"key":"10.1016\/bs.apcsb.2019.08.009_bib39","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3389\/fimmu.2013.00323","article-title":"Messages from the inside. The dynamic environment that favors intestinal homeostasis","volume":"4","author":"Eri","year":"2013","journal-title":"Frontiers in Immunology"},{"issue":"1","key":"10.1016\/bs.apcsb.2019.08.009_bib40","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/17474124.2018.1378573","article-title":"The role of mucoprotectants in the management of gastrointestinal disorders","volume":"12","author":"Eutamene","year":"2018","journal-title":"Expert Review of Gastroenterology & Hepatology"},{"issue":"4","key":"10.1016\/bs.apcsb.2019.08.009_bib41","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1053\/gast.2003.50145","article-title":"Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: A randomized controlled trial","volume":"124","author":"Farrell","year":"2003","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/bs.apcsb.2019.08.009_bib42","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1681\/ASN.2005121359","article-title":"Is there a role for TNF-\u03b1 in anti-neutrophil cytoplasmic antibody\u2013associated vasculitis? Lessons from other chronic inflammatory diseases","volume":"17","author":"Feldmann","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1016\/bs.apcsb.2019.08.009_bib45","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1084\/jem.170.5.1627","article-title":"Antibodies to cachectin\/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia","volume":"170","author":"Fong","year":"1989","journal-title":"Journal of Experimental Medicine"},{"issue":"4","key":"10.1016\/bs.apcsb.2019.08.009_bib46","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/ajg.2011.70","article-title":"Glucocorticosteroid therapy in inflammatory bowel disease: Systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"American Journal of Gastroenterology"},{"issue":"42","key":"10.1016\/bs.apcsb.2019.08.009_bib47","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.3748\/wjg.15.5287","article-title":"Mucosal bacterial microflora and mucus layer thickness in adolescents with inflammatory bowel disease","volume":"15","author":"Fyderek","year":"2009","journal-title":"World Journal of Gastroenterology"},{"issue":"5","key":"10.1016\/bs.apcsb.2019.08.009_bib48","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1136\/gut.2007.140210","article-title":"Increased faecal serine protease activity in diarrhoeic IBS patients: A colonic lumenal factor impairing colonic permeability and sensitivity","volume":"57","author":"Gecse","year":"2008","journal-title":"Gut"},{"issue":"2","key":"10.1016\/bs.apcsb.2019.08.009_bib49","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.annemergmed.2017.04.034","article-title":"The efficacy of crotalidae polyvalent immune Fab (ovine) antivenom versus placebo plus optional rescue therapy on recovery from copperhead snake envenomation: A randomized, double-blind, placebo-controlled, clinical trial","volume":"70","author":"Gerardo","year":"2017","journal-title":"Annals of Emergency Medicine"},{"issue":"3","key":"10.1016\/bs.apcsb.2019.08.009_bib50","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1136\/flgastro-2014-100514","article-title":"A UK cost of care model for inflammatory bowel disease","volume":"6","author":"Ghosh","year":"2015","journal-title":"Frontline Gastroenterology"},{"issue":"33","key":"10.1016\/bs.apcsb.2019.08.009_bib52","doi-asserted-by":"crossref","first-page":"6137","DOI":"10.3748\/wjg.v23.i33.6137","article-title":"Patients with inflammatory bowel disease have increased risk of autoimmune and inflammatory diseases","volume":"23","author":"Halling","year":"2017","journal-title":"World Journal of Gastroenterology"},{"issue":"9317","key":"10.1016\/bs.apcsb.2019.08.009_bib53","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"The Lancet"},{"issue":"2","key":"10.1016\/bs.apcsb.2019.08.009_bib54","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: The CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/bs.apcsb.2019.08.009_bib55","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/ecco-jcc\/jjw036","article-title":"AVX-470, an orally delivered anti-tumour necrosis factor antibody for treatment of active ulcerative colitis: Results of a first-in-human trial","volume":"10","author":"Harris","year":"2016","journal-title":"Journal of Crohn\u2019s & Colitis"},{"issue":"6","key":"10.1016\/bs.apcsb.2019.08.009_bib56","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1093\/ecco-jcc\/jjw026","article-title":"Effects of AVX-470, an oral, locally acting anti-tumour necrosis factor antibody, on tissue biomarkers in patients with active ulcerative colitis","volume":"10","author":"Hartman","year":"2016","journal-title":"Journal of Crohn\u2019s & Colitis"},{"issue":"7","key":"10.1016\/bs.apcsb.2019.08.009_bib57","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1271\/bbb.57.1077","article-title":"Oral passive immunization effect of anti-human rotavirus IgY and its behaviour against proteolytic enzymes","volume":"57","author":"Hatta","year":"1993","journal-title":"Bioscience Biotechnology and Biochemistry"},{"issue":"2","key":"10.1016\/bs.apcsb.2019.08.009_bib58","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.gastro.2005.05.002","article-title":"Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution","volume":"129","author":"Heller","year":"2005","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/bs.apcsb.2019.08.009_bib59","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/j.1572-0241.2005.00356.x","article-title":"Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's disease","volume":"101","author":"Herrlinger","year":"2006","journal-title":"American Journal of Gastroenterology"},{"issue":"1","key":"10.1016\/bs.apcsb.2019.08.009_bib60","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/infdis\/156.1.158","article-title":"Use of bovine milk concentrate containing antibody to rotavirus to treat rotavirus gastroenteritis in infants","volume":"156","author":"Hilpert","year":"1987","journal-title":"The Journal of Infectious Diseases"},{"issue":"3","key":"10.1016\/bs.apcsb.2019.08.009_bib61","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.pharmthera.2012.10.008","article-title":"Immune aspects of the pathogenesis of inflammatory bowel disease","volume":"137","author":"Hisamatsu","year":"2013","journal-title":"Pharmacology & Therapeutics"},{"issue":"7","key":"10.1016\/bs.apcsb.2019.08.009_bib64","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/rheumatology\/keq031","article-title":"Transmembrane TNF-alpha: Structure, function and interaction with anti-TNF agents","volume":"49","author":"Horiuchi","year":"2010","journal-title":"Rheumatology"},{"issue":"12","key":"10.1016\/bs.apcsb.2019.08.009_bib65","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: Unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"issue":"10","key":"10.1016\/bs.apcsb.2019.08.009_bib66","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1006\/cyto.1998.0492","article-title":"Modes of L929 cell death induced by TNF-alpha and other cytotoxic agents","volume":"11","author":"Humphreys","year":"1999","journal-title":"Cytokine"},{"issue":"9","key":"10.1016\/bs.apcsb.2019.08.009_bib67","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.4049\/jimmunol.152.9.4663","article-title":"Oral tolerance in humans. T cell but not B cell tolerance after antigen feeding","volume":"152","author":"Husby","year":"1994","journal-title":"The Journal of Immunology"},{"issue":"1","key":"10.1016\/bs.apcsb.2019.08.009_bib69","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1136\/gut.2010.219683","article-title":"Antibiotic use and inflammatory bowel diseases in childhood","volume":"60","author":"Hviid","year":"2011","journal-title":"Gut"},{"issue":"3","key":"10.1016\/bs.apcsb.2019.08.009_bib71","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.imbio.2016.11.001","article-title":"A plant cell-expressed recombinant anti-TNF fusion protein is biologically active in the gut and alleviates immune-mediated hepatitis and colitis","volume":"222","author":"Ilan","year":"2017","journal-title":"Immunobiology"},{"key":"10.1016\/bs.apcsb.2019.08.009_bib72","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12937-015-0010-7","article-title":"Survival and digestibility of orally-administered immunoglobulin preparations containing IgG through the gastrointestinal tract in humans","volume":"14","author":"Jasion","year":"2015","journal-title":"Nutrition Journal"},{"issue":"2","key":"10.1016\/bs.apcsb.2019.08.009_bib73","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1136\/gutjnl-2012-303207","article-title":"Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis","volume":"63","author":"Johansson","year":"2014","journal-title":"Gut"},{"issue":"1","key":"10.1016\/bs.apcsb.2019.08.009_bib74","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0022-1759(03)00005-X","article-title":"A protocol for \u2018enhanced pepsin digestion\u2019: A step by step method for obtaining pure antibody fragments in high yield from serum","volume":"275","author":"Jones","year":"2003","journal-title":"Journal of Immunological Methods"},{"issue":"3","key":"10.1016\/bs.apcsb.2019.08.009_bib75","first-page":"506","article-title":"Targeted localized use of therapeutic antibodies: A review of non-systemic, topical and oral applications","volume":"36","author":"Jones","year":"2016","journal-title":"Critical Reviews in Biotechnology"},{"issue":"Suppl 1","key":"10.1016\/bs.apcsb.2019.08.009_bib187","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1093\/jcag\/gwy048","article-title":"The Impact of Inflammatory Bowel Disease in Canada 2018: Quality of Life","volume":"2","author":"Jones","year":"2019","journal-title":"Journal of the Canadian Association of Gastroenterology"},{"issue":"7422","key":"10.1016\/bs.apcsb.2019.08.009_bib76","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nature11582","article-title":"Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease","volume":"491","author":"Jostins","year":"2012","journal-title":"Nature"},{"issue":"11","key":"10.1016\/bs.apcsb.2019.08.009_bib79","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1080\/00365521.2017.1347812","article-title":"The potential role of fecal microbiota transplantation in the treatment of inflammatory bowel disease","volume":"52","author":"Khajah","year":"2017","journal-title":"Scandinavian Journal of Gastroenterology"},{"issue":"5","key":"10.1016\/bs.apcsb.2019.08.009_bib80","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1128\/IAI.66.5.2018-2025.1998","article-title":"Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection","volume":"66","author":"Kink","year":"1998","journal-title":"Infection and Immunity"},{"issue":"3","key":"10.1016\/bs.apcsb.2019.08.009_bib81","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1021\/acs.biomac.5b01518","article-title":"Enzyme- and pH-responsive microencapsulated nanogels for oral delivery of siRNA to induce TNF-\u03b1 knockdown in the intestine","volume":"17","author":"Knipe","year":"2016","journal-title":"Biomacromolecules"},{"issue":"4","key":"10.1016\/bs.apcsb.2019.08.009_bib83","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/00054725-199811000-00014","article-title":"Infliximab approved for use in Crohn's disease: A report on the FDA GI advisory committee conference","volume":"4","author":"Kornbluth","year":"1998","journal-title":"Inflammatory Bowel Diseases"},{"issue":"2","key":"10.1016\/bs.apcsb.2019.08.009_bib84","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1053\/j.gastro.2012.04.045","article-title":"Loss of interleukin-10 signaling and infantile inflammatory bowel disease: Implications for diagnosis and therapy","volume":"143","author":"Kotlarz","year":"2012","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/bs.apcsb.2019.08.009_bib85","doi-asserted-by":"crossref","first-page":"e794","DOI":"10.1542\/peds.2011-3886","article-title":"Antibiotic exposure and IBD development among children: A population-based cohort study","volume":"130","author":"Kronman","year":"2012","journal-title":"Pediatrics"},{"issue":"19","key":"10.1016\/bs.apcsb.2019.08.009_bib87","doi-asserted-by":"crossref","first-page":"13799","DOI":"10.1074\/jbc.M112.433961","article-title":"Structural basis for treating tumor necrosis factor \u03b1 (TNF\u03b1)-associated diseases with the therapeutic antibody infliximab","volume":"288","author":"Liang","year":"2013","journal-title":"Journal of Biological Chemistry"},{"issue":"3","key":"10.1016\/bs.apcsb.2019.08.009_bib88","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1600-0722.2005.00216.x","article-title":"Effects of the tumour necrosis factor-alpha inhibitors pentoxifylline and thalidomide in short-term experimental oral mucositis in hamsters","volume":"113","author":"Lima","year":"2005","journal-title":"European Journal of Oral Sciences"},{"issue":"3","key":"10.1016\/bs.apcsb.2019.08.009_bib188","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/ilar.46.3.258","article-title":"Monoclonal versus polyclonal antibodies: distinguishing characteristics, applications, and information resources","volume":"46","author":"Lipman","year":"2005","journal-title":"ILAR Journal"},{"issue":"3","key":"10.1016\/bs.apcsb.2019.08.009_bib89","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1080\/17425247.2017.1395853","article-title":"Strategies and industrial perspectives to improve oral absorption of biological macromolecules","volume":"15","author":"Liu","year":"2018","journal-title":"Expert Opinion on Drug Delivery"},{"issue":"6864","key":"10.1016\/bs.apcsb.2019.08.009_bib90","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1136\/bmj.305.6864.1269","article-title":"Discovery of antibodies","volume":"305","author":"Llewelyn","year":"1992","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/bs.apcsb.2019.08.009_bib91","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/MOG.0b013e32816aa392","article-title":"Altered permeability in inflammatory bowel disease: Pathophysiology and clinical implications","volume":"23","author":"Mankertz","year":"2007","journal-title":"Current Opinion in Gastroenterology"},{"issue":"14","key":"10.1016\/bs.apcsb.2019.08.009_bib92","doi-asserted-by":"crossref","first-page":"8366","DOI":"10.1073\/pnas.1432897100","article-title":"TNF-alpha neutralization ameliorates the severity of murine Crohn\u2019s-like ileitis by abrogation of intestinal epithelial cell apoptosis","volume":"100","author":"Marini","year":"2003","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"0","key":"10.1016\/bs.apcsb.2019.08.009_bib93","first-page":"1","article-title":"Risks associated with use of TNF inhibitors in children with rheumatic diseases","volume":"0","author":"Marino","year":"2018","journal-title":"Expert Review of Clinical Immunology"},{"issue":"1\u20132","key":"10.1016\/bs.apcsb.2019.08.009_bib95","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ijpharm.2016.03.027","article-title":"Development and potential application of an oral ColoPulse infliximab tablet with colon specific release: A feasibility study","volume":"505","author":"Maurer","year":"2016","journal-title":"International Journal of Pharmaceutics"},{"issue":"10","key":"10.1016\/bs.apcsb.2019.08.009_bib96","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1002\/art.38755","article-title":"Selective tumor necrosis factor receptor I blockade is anti-inflammatory and reveals immunoregulatory role of tumor necrosis factor receptor II in collagen-induced arthritis","volume":"66","author":"McCann","year":"2014","journal-title":"Arthritis & Rheumatology (Hoboken, N.J.)"},{"issue":"Suppl. 1","key":"10.1016\/bs.apcsb.2019.08.009_bib98","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/14740338.2016.1240783","article-title":"Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: A systematic review and meta-analysis","volume":"15","author":"Minozzi","year":"2016","journal-title":"Expert Opinion on Drug Safety"},{"issue":"2","key":"10.1016\/bs.apcsb.2019.08.009_bib99","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1053\/j.gastro.2004.11.060","article-title":"Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha","volume":"128","author":"Mitoma","year":"2005","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/bs.apcsb.2019.08.009_bib100","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/BF02779504","article-title":"Significance of interleukin-6 in patients with inflammatory bowel disease","volume":"26","author":"Mitsuyama","year":"1991","journal-title":"Gastroenterologia Japonica"},{"key":"10.1016\/bs.apcsb.2019.08.009_bib101","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.trsl.2016.06.002","article-title":"The gut microbiota and inflammatory bowel diseases","volume":"179","author":"Miyoshi","year":"2017","journal-title":"Translational Research: The Journal of Laboratory and Clinical Medicine"},{"issue":"1","key":"10.1016\/bs.apcsb.2019.08.009_bib102","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/intimm\/dxu102","article-title":"Anti-TNF therapy: Past, present and future","volume":"27","author":"Monaco","year":"2015","journal-title":"International Immunology"},{"issue":"3","key":"10.1016\/bs.apcsb.2019.08.009_bib103","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/0016-5085(89)90904-9","article-title":"Hapten-induced model of chronic inflammation and ulceration in the rat colon","volume":"96","author":"Morris","year":"1989","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/bs.apcsb.2019.08.009_bib104","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1542-3565(05)00208-9","article-title":"Interferon-beta-1a for the treatment of steroid-refractory ulcerative colitis: A randomized, double-blind, placebo-controlled trial","volume":"3","author":"Musch","year":"2005","journal-title":"Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association"},{"issue":"6","key":"10.1016\/bs.apcsb.2019.08.009_bib105","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.imbio.2007.03.002","article-title":"Allergies, infections and the hygiene hypothesis - the epidemiological evidence","volume":"212","author":"von Mutius","year":"2007","journal-title":"Immunobiology"},{"issue":"3","key":"10.1016\/bs.apcsb.2019.08.009_bib106","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.immuni.2010.03.001","article-title":"Interferon-gamma regulates intestinal epithelial homeostasis through converging beta-catenin signalling pathways","volume":"32","author":"Nava","year":"2010","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/bs.apcsb.2019.08.009_bib107","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nrmicro2403","article-title":"The impact of the microbiota on the pathogenesis of IBD: Lessons from mouse infection models","volume":"8","author":"Nell","year":"2010","journal-title":"Nature Reviews Microbiology"},{"issue":"8","key":"10.1016\/bs.apcsb.2019.08.009_bib109","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/ni.3790","article-title":"A guiding map for inflammation","volume":"18","author":"Netea","year":"2017","journal-title":"Nature Immunology"},{"issue":"5","key":"10.1016\/bs.apcsb.2019.08.009_bib110","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nri3661","article-title":"Cytokines in inflammatory bowel disease","volume":"14","author":"Neurath","year":"2014","journal-title":"Nature Reviews Immunology"},{"issue":"11","key":"10.1016\/bs.apcsb.2019.08.009_bib111","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nrgastro.2017.138","article-title":"Current and emerging therapeutic targets for IBD","volume":"14","author":"Neurath","year":"2017","journal-title":"Nature Reviews Gastroenterology & Hepatology"},{"key":"10.1016\/bs.apcsb.2019.08.009_bib112","doi-asserted-by":"crossref","DOI":"10.1038\/s41590-019-0415-0","article-title":"Targeting immune cell circuits and trafficking in inflammatory bowel disease","author":"Neurath","year":"2019","journal-title":"Nature Immunology"},{"issue":"6","key":"10.1016\/bs.apcsb.2019.08.009_bib113","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/nm0602-567","article-title":"The role of Th1\/Th2 polarization in mucosal immunity","volume":"8","author":"Neurath","year":"2002","journal-title":"Nature Medicine"},{"issue":"1","key":"10.1016\/bs.apcsb.2019.08.009_bib114","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jchromb.2006.07.004","article-title":"Antibody production: Polyclonal-derived biotherapeutics","volume":"848","author":"Newcombe","year":"2007","journal-title":"Journal of Chromatography B"},{"issue":"4","key":"10.1016\/bs.apcsb.2019.08.009_bib115","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1136\/gutjnl-2012-303661","article-title":"Geographical variability and environmental risk factors in inflammatory bowel disease","volume":"62","author":"Ng","year":"2013","journal-title":"Gut"},{"issue":"1","key":"10.1016\/bs.apcsb.2019.08.009_bib122","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.MIB.0000436951.80898.6d","article-title":"Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: A systematic review and meta-analysis","volume":"20","author":"O'Meara","year":"2014","journal-title":"Inflammatory Bowel Diseases"},{"issue":"2","key":"10.1016\/bs.apcsb.2019.08.009_bib123","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1615\/CritRevEukarGeneExpr.v20.i2.10","article-title":"Tumor necrosis factor-\u03b1 signaling in macrophages","volume":"20","author":"Parameswaran","year":"2010","journal-title":"Critical Reviews in Eukaryotic Gene Expression"},{"issue":"12","key":"10.1016\/bs.apcsb.2019.08.009_bib124","first-page":"741","article-title":"The role of biosimilars in inflammatory bowel disease","volume":"12","author":"Paramsothy","year":"2016","journal-title":"Gastroenterology and Hepatology"},{"issue":"2366","key":"10.1016\/bs.apcsb.2019.08.009_bib125","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1136\/bmj.1.2366.1032","article-title":"Serumtherapy by the mouth","volume":"1","author":"Paton","year":"1906","journal-title":"British Medical Journal"},{"issue":"3","key":"10.1016\/bs.apcsb.2019.08.009_bib126","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1159\/000493922","article-title":"Severe de novo ulcerative colitis following ixekizumab therapy","volume":"12","author":"Philipose","year":"2018","journal-title":"Case Reports in Gastroenterology"},{"issue":"5","key":"10.1016\/bs.apcsb.2019.08.009_bib127","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3109\/08820138009066011","article-title":"Antibodies to proteins from yolk of immunized hens","volume":"9","author":"Polson","year":"1980","journal-title":"Immunological Communications"},{"issue":"7","key":"10.1016\/bs.apcsb.2019.08.009_bib128","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/1074-7613(94)90045-0","article-title":"Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells","volume":"1","author":"Powrie","year":"1994","journal-title":"Immunity"},{"key":"10.1016\/bs.apcsb.2019.08.009_bib129","unstructured":"Press Releases by Protalix Biotherapeutics [Company website]. (October 25, 2018). Retrieved 25 October 2018, from http:\/\/phx.corporate-ir.net\/phoenix.zhtml?c=101161&p=irol-newsArticle&ID=2324351"},{"issue":"15","key":"10.1016\/bs.apcsb.2019.08.009_bib130","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.3748\/wjg.v18.i15.1708","article-title":"Etiology of inflammatory bowel disease: A unified hypothesis","volume":"18","author":"Qin","year":"2012","journal-title":"World Journal of Gastroenterology: WJG"},{"issue":"2","key":"10.1016\/bs.apcsb.2019.08.009_bib131","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1097\/MIB.0000000000001010","article-title":"Damage of the mucus layer: The possible shared critical common cause for both inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS)","volume":"23","author":"Qin","year":"2017","journal-title":"Inflammatory Bowel Diseases"},{"issue":"1","key":"10.1016\/bs.apcsb.2019.08.009_bib133","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.mayocp.2018.09.013","article-title":"Mechanisms of disease: Inflammatory bowel diseases","volume":"94","author":"Ramos","year":"2019","journal-title":"Mayo Clinic Proceedings"},{"issue":"8","key":"10.1016\/bs.apcsb.2019.08.009_bib134","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/gut.2005.079434","article-title":"A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease","volume":"55","author":"Reinisch","year":"2006","journal-title":"Gut"},{"issue":"6","key":"10.1016\/bs.apcsb.2019.08.009_bib135","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.it.2011.04.003","article-title":"The intestinal epithelial barrier in the control of homeostasis and immunity","volume":"32","author":"Rescigno","year":"2011","journal-title":"Trends in Immunology"},{"issue":"5","key":"10.1016\/bs.apcsb.2019.08.009_bib136","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.cgh.2006.12.004","article-title":"A pilot study of fecal serine-protease activity: A pathophysiologic factor in diarrhea-predominant irritable bowel syndrome","volume":"5","author":"R\u00f3ka","year":"2007","journal-title":"Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association"},{"key":"10.1016\/bs.apcsb.2019.08.009_bib137","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1600-065X.2008.00713.x","article-title":"Welcome to the neighborhood: Epithelial cell-derived cytokines license innate and adaptive immune responses at mucosal sites","volume":"226","author":"Saenz","year":"2008","journal-title":"Immunological Reviews"},{"issue":"1","key":"10.1016\/bs.apcsb.2019.08.009_bib138","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/j.gastro.2013.06.010","article-title":"Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/bs.apcsb.2019.08.009_bib139","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa067594","article-title":"Certolizumab pegol for the treatment of Crohn's disease","volume":"357","author":"Sandborn","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1016\/bs.apcsb.2019.08.009_bib140","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/bs.apcsb.2019.08.009_bib141","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/bs.apcsb.2019.08.009_bib144","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1053\/j.gastro.2007.11.059","article-title":"Microbial influences in inflammatory bowel diseases","volume":"134","author":"Sartor","year":"2008","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/bs.apcsb.2019.08.009_bib145","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1080\/09546630410017275","article-title":"A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab","volume":"15","author":"Scheinfeld","year":"2004","journal-title":"Journal of Dermatological Treatment"},{"issue":"2","key":"10.1016\/bs.apcsb.2019.08.009_bib146","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0016-5085(99)70126-5","article-title":"Altered tight junction structure contributes to the impaired epithelial barrier function in ulcerative colitis","volume":"116","author":"Schmitz","year":"1999","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/bs.apcsb.2019.08.009_bib147","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0016-5085(99)70393-8","article-title":"The intestinal mucus layer from patients with inflammatory bowel disease harbors high numbers of bacteria compared with controls","volume":"117","author":"Schultsz","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/bs.apcsb.2019.08.009_bib150","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/2097274","article-title":"The immunological basis of inflammatory bowel disease","author":"Silva","year":"2016","journal-title":"Gastroenterology Research and Practice"},{"issue":"4","key":"10.1016\/bs.apcsb.2019.08.009_bib151","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nrmicro2540","article-title":"Unravelling the effects of the environment and host genotype on the gut microbiome","volume":"9","author":"Spor","year":"2011","journal-title":"Nature Reviews Microbiology"},{"issue":"11","key":"10.1016\/bs.apcsb.2019.08.009_bib152","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1136\/gutjnl-2011-300775","article-title":"Bacterial proteases in IBD and IBS","volume":"61","author":"Steck","year":"2012","journal-title":"Gut"},{"issue":"6","key":"10.1016\/bs.apcsb.2019.08.009_bib153","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1053\/j.gastro.2011.02.016","article-title":"Pro-inflammatory cytokines in the pathogenesis of IBD","volume":"140","author":"Strober","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/bs.apcsb.2019.08.009_bib154","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1146\/annurev.immunol.20.100301.064816","article-title":"The immunology of mucosal models of inflammation","volume":"20","author":"Strober","year":"2002","journal-title":"Annual Review of Immunology"},{"issue":"5","key":"10.1016\/bs.apcsb.2019.08.009_bib155","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/j.1742-1241.2007.01665.x","article-title":"Thickness and continuity of the adherent colonic mucus barrier in active and quiescent ulcerative colitis and Crohn's disease","volume":"62","author":"Strugala","year":"2008","journal-title":"International Journal of Clinical Practice"},{"issue":"2","key":"10.1016\/bs.apcsb.2019.08.009_bib156","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1053\/j.gastro.2013.04.011","article-title":"TNFR2 activates MLCK-dependent tight junction dysregulation to cause apoptosis-mediated barrier loss and experimental colitis","volume":"145","author":"Su","year":"2013","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/bs.apcsb.2019.08.009_bib160","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.tim.2008.07.005","article-title":"The search for disease-associated compositional shifts in bowel bacterial communities of humans","volume":"16","author":"Tannock","year":"2008","journal-title":"Trends in Microbiology"},{"issue":"7","key":"10.1016\/bs.apcsb.2019.08.009_bib161","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1517\/14712598.7.7.1051","article-title":"Mode of function of biological anti-TNF agents in the treatment of inflammatory bowel diseases","volume":"7","author":"Tilg","year":"2007","journal-title":"Expert Opinion on Biological Therapy"},{"issue":"4","key":"10.1016\/bs.apcsb.2019.08.009_bib162","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.4049\/jimmunol.169.4.2204","article-title":"Role of IL-10 for induction of anemia during inflammation","volume":"169","author":"Tilg","year":"2002","journal-title":"The Journal of Immunology"},{"key":"10.1016\/bs.apcsb.2019.08.009_bib163","first-page":"CD000478","article-title":"Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis","volume":"5","author":"Timmer","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1016\/bs.apcsb.2019.08.009_bib164","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1651-2227.1997.tb08873.x","article-title":"Oral immunoglobulin treatment in Crohn's disease","volume":"86","author":"Tjellstr\u00f6m","year":"1997","journal-title":"Acta Paediatrica"},{"issue":"10080","key":"10.1016\/bs.apcsb.2019.08.009_bib165","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn's disease","volume":"389","author":"Torres","year":"2017","journal-title":"The Lancet"},{"issue":"40","key":"10.1016\/bs.apcsb.2019.08.009_bib166","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.3748\/wjg.v16.i40.5024","article-title":"Health related quality of life in inflammatory bowel disease: The impact of surgical therapy","volume":"16","author":"Umanskiy","year":"2010","journal-title":"World Journal of Gastroenterology"},{"issue":"11","key":"10.1016\/bs.apcsb.2019.08.009_bib167","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1038\/ajg.2014.246","article-title":"Antibiotics associated with increased risk of new-onset Crohn's disease but not\u00a0ulcerative colitis: A meta-analysis","volume":"109","author":"Ungaro","year":"2014","journal-title":"American Journal of Gastroenterology"},{"issue":"10080","key":"10.1016\/bs.apcsb.2019.08.009_bib168","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"The Lancet"},{"key":"10.1016\/bs.apcsb.2019.08.009_bib169","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nrd.2018.42","article-title":"Market watch: Top drugs and companies by sales in 2017","volume":"17","author":"Urquhart","year":"2018","journal-title":"Nature Reviews Drug Discovery"},{"issue":"12","key":"10.1016\/bs.apcsb.2019.08.009_bib170","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.3748\/wjg.v23.i12.2106","article-title":"Regulation of intestinal permeability: The role of proteases","volume":"23","author":"Van Spaendonk","year":"2017","journal-title":"World Journal of Gastroenterology"},{"issue":"1","key":"10.1016\/bs.apcsb.2019.08.009_bib171","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/mi.2009.116","article-title":"Orally administered L. lactis secreting an anti-TNF nanobody demonstrate efficacy in chronic colitis","volume":"3","author":"Vandenbroucke","year":"2010","journal-title":"Mucosal Immunology"},{"issue":"1","key":"10.1016\/bs.apcsb.2019.08.009_bib172","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1053\/j.gastro.2006.04.020","article-title":"Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection","volume":"131","author":"Van der Sluis","year":"2006","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/bs.apcsb.2019.08.009_bib173","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/aje\/kwr400","article-title":"Association of repeated exposure to antibiotics with the development of pediatric Crohn's disease\u00e2\u20ac\u201dA nationwide, register-based Finnish case-control study","volume":"175","author":"Virta","year":"2012","journal-title":"American Journal of Epidemiology"},{"key":"10.1016\/bs.apcsb.2019.08.009_bib174","first-page":"CD000544","article-title":"Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis","volume":"5","author":"Wang","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1016\/bs.apcsb.2019.08.009_bib175","doi-asserted-by":"crossref","first-page":"G973","DOI":"10.1152\/ajpgi.00017.2016","article-title":"Insights into the pathogenesis of ulcerative colitis from a murine model of stasis-induced dysbiosis, colonic metaplasia, and genetic susceptibility","volume":"310","author":"Ward","year":"2016","journal-title":"American Journal of Physiology - Gastrointestinal and Liver Physiology"},{"issue":"5","key":"10.1016\/bs.apcsb.2019.08.009_bib177","first-page":"72","article-title":"Inflammatory bowel disease","volume":"113","author":"Wehkamp","year":"2016","journal-title":"Deutsches Arzteblatt International"},{"issue":"10","key":"10.1016\/bs.apcsb.2019.08.009_bib178","first-page":"666","article-title":"Optimization of treatment by antibodies against TNF-\u03b1 in inflammatory bowel disease","volume":"156","author":"Weisshof","year":"2017","journal-title":"Harefuah"},{"issue":"5","key":"10.1016\/bs.apcsb.2019.08.009_bib179","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nm.4307","article-title":"Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease","volume":"23","author":"West","year":"2017","journal-title":"Nature Medicine"},{"issue":"3","key":"10.1016\/bs.apcsb.2019.08.009_bib180","article-title":"Management of patients with inflammatory bowel disease: Current and future treatments","volume":"9","author":"Wilhelm","year":"2017","journal-title":"Clinical Pharmacist"},{"issue":"2","key":"10.1016\/bs.apcsb.2019.08.009_bib181","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0022-1759(94)00263-V","article-title":"Comparison of antibody production to human interleukin-6 (IL-6) by sheep and chickens","volume":"178","author":"Woolley","year":"1995","journal-title":"Journal of Immunological Methods"},{"issue":"12","key":"10.1016\/bs.apcsb.2019.08.009_bib182","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1023\/A:1005554900286","article-title":"Oral administration of avian tumor necrosis factor antibodies effectively treats experimental colitis in rats","volume":"45","author":"Worledge","year":"2000","journal-title":"Digestive Diseases and Sciences"},{"key":"10.1016\/bs.apcsb.2019.08.009_bib183","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.mehy.2018.08.013","article-title":"Mucus protectors: Promising therapeutic strategies for inflammatory bowel disease","volume":"120","author":"Wu","year":"2018","journal-title":"Medical Hypotheses"},{"issue":"1","key":"10.1016\/bs.apcsb.2019.08.009_bib184","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/gut.2006.094375","article-title":"Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease","volume":"56","author":"Zeissig","year":"2007","journal-title":"Gut"},{"issue":"7","key":"10.1016\/bs.apcsb.2019.08.009_bib185","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00011-013-0633-0","article-title":"TNF-\u03b1 signalling and inflammation: Interactions between old acquaintances","volume":"62","author":"Zelov\u00e1","year":"2013","journal-title":"Inflammation Research: Official Journal of the European Histamine Research Society"},{"issue":"11","key":"10.1016\/bs.apcsb.2019.08.009_bib186","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1002\/ibd.21611","article-title":"Suppression of hath1 gene expression directly regulated by hes1 via notch signalling is associated with goblet cell depletion in ulcerative colitis","volume":"17","author":"Zheng","year":"2011","journal-title":"Inflammatory Bowel Diseases"}],"container-title":["Advances in Protein Chemistry and Structural Biology","Inflammatory Disorders, Part A"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187616231930063X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187616231930063X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T16:19:25Z","timestamp":1761754765000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187616231930063X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9780128168448"],"references-count":152,"URL":"https:\/\/doi.org\/10.1016\/bs.apcsb.2019.08.009","relation":{},"ISSN":["1876-1623"],"issn-type":[{"value":"1876-1623","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}